NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Comparing the Efficacy and Safety of High-Titer Versus Low-Titer Anti-Influenza Immune Plasma for the Treatment of Severe Influenza A

Phase 3

Completed

Conditions: Influenza A Virus Infection

Interventions: Biological: High-titer anti-influenza plasma
Biological: Low-titer anti-influenza plasma

First Posted Date: 2015-10-09

Last Posted Date: 2019-06-25

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 138

Registration Number: NCT02572817

Locations: 🇺🇸
Beaumont Hospital - Royal Oak, Royal Oak, Michigan, United States
🇺🇸
Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸
UCLA Pediatrics Infectious Diseases, Los Angeles, California, United States

and more 27 locations

Evaluating the Safety and Efficacy of the VRC01 Antibody in Reducing Acquisition of HIV-1 Infection in Women

Phase 2

Completed

Conditions: HIV Infections

Interventions: Biological: Placebo for VRC01
Biological: VRC01

First Posted Date: 2015-10-05

Last Posted Date: 2022-02-23

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 1924

Registration Number: NCT02568215

Locations: 🇧🇼
Gaborone CRS, Gaborone, South-East District, Botswana
🇰🇪
Kisumu Crs, Kisumu, Nyanza, Kenya
🇲🇼
Malawi CRS, Lilongwe, Malawi

and more 18 locations

Evaluating the Safety of and Immune Response to a Human Parainfluenza Virus Type 3 Ebola Virus Vaccine (HPIV3-EbovZ GP) in Healthy Adults

Phase 1

Completed

Conditions: Hemorrhagic Fever, Ebola

Interventions: Biological: HPIV3-EbovZ GP Vaccine

First Posted Date: 2015-09-30

Last Posted Date: 2017-02-01

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 30

Registration Number: NCT02564575

Locations: 🇺🇸
Center for Immunization Research (CIR), Johns Hopkins Bloomberg School of Public Health (JHBSPH), Baltimore, Maryland, United States

Trial for Safety and Immunogenicity of a Chikungunya Vaccine, VRC-CHKVLP059-00-VP, in Healthy Adults

Phase 2

Completed

Conditions: Chikungunya Virus Infection

Interventions: Biological: VRC-CHKVLP059-00-VP
Other: VRC-PBSPLA043-00-VP

First Posted Date: 2015-09-29

Last Posted Date: 2020-10-22

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 400

Registration Number: NCT02562482

Locations: 🇵🇷
Puerto Rico Clinical and Translational Research Consortium, San Juan, Puerto Rico
🇭🇹
Centres GHESKIO, Port Au Prince, Haiti
🇲🇶
Centre Hospitalier Universitaire (CHU), Martinique, Fort-de-France, Martinique

and more 3 locations

Emtricitabine/Tenofovir Alafenamide as Salvage ART

Phase 2

Terminated

Conditions: HIV

Interventions: Drug: FTC/TAF

First Posted Date: 2015-09-22

Last Posted Date: 2017-11-14

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 1

Registration Number: NCT02556333

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Markers of T Cell Suppression: Antimalarial Treatment and Vaccine Responses in Healthy Malian Adults

Completed

Conditions: Malaria

First Posted Date: 2015-09-09

Last Posted Date: 2019-12-17

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 49

Registration Number: NCT02544048

Locations: 🇲🇱
Malaria Research and Training Center, Bamako, Mali

Sputum Pharmacokinetics of TB Drugs and Bacterial Drug Resistance

Completed

Conditions: Non-Tuberculosis Mycobacteria
Tuberculosis

First Posted Date: 2015-08-28

Last Posted Date: 2022-03-29

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 215

Registration Number: NCT02534727

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
🇨🇳
Henan Provincial Chest Hospital, Zhengzhou,, China

Evaluation of Donor Specific Immune Senescence and Exhaustion as Biomarkers of Tolerance Post Liver Transplantation

Phase 2

Completed

Conditions: Liver Transplantation
Liver Transplant

Interventions: Biological: Immunosuppression withdrawal

First Posted Date: 2015-08-26

Last Posted Date: 2023-09-14

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 100

Registration Number: NCT02533180

Locations: 🇺🇸
University of California, San Francisco Medical Center, San Francisco, California, United States
🇺🇸
Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

and more 4 locations

Subcutaneous Immunotherapy for Mouse in Adults

Phase 1

Completed

Conditions: Asthma
Perennial Allergic Rhinitis

Interventions: Biological: Mouse Allergenic Extract

First Posted Date: 2015-08-25

Last Posted Date: 2018-03-07

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 12

Registration Number: NCT02532179

Locations: 🇺🇸
Ann and Robert Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
🇺🇸
Johns Hopkins Children's Center: Department of Allergy & Immunology, Baltimore, Maryland, United States
🇺🇸
Henry Ford Health System: Division of Allergy and Immunology, Detroit, Michigan, United States

and more 1 locations

Phase 1 Study of dmLT ID Vaccination in Healthy Adults

Phase 1

Completed

Conditions: Gastroenteritis Escherichia Coli

Interventions: Other: Placebo
Biological: Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine

First Posted Date: 2015-08-24

Last Posted Date: 2020-10-26

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 100

Registration Number: NCT02531685

Locations: 🇺🇸
Cincinnati Children's Hospital Medical Center - Infectious Diseases, Cincinnati, Ohio, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy